Jaguar Health announces results of veterinary oncologists on Canalevia-CA1

Jaguar Health (JAGX) announced the results of a new survey of 27 board certified veterinary oncologists practicing in the U.S. regarding Canalevia-CA1 and the treatment of chemotherapy-induced diarrhea in dogs. Canalevia-CA1, the company’s U.S. Food and Drug Administration conditionally approved prescription drug product for the treatment of CID in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy. Of the veterinary oncologists who participated in the survey, 20 indicated that, due to concerns about antibiotic resistance, they felt it was somewhat important to extremely important that Canalevia-CA1 is not an antimicrobial. Other key highlights of the survey of veterinary oncologists include: Of the 24 participants who responded to the question “When managing CID in dogs, which statement best describes your view of metronidazole as a treatment option?”, 15 indicated that they are concerned with antimicrobial resistance when treating dogs for CID, and prefer not to use metronidazole for the treatment of CID in dogs. Of the 24 participants who responded to the question “When a dog experiences CID, how big of a negative impact does this have on the dog’s ability to stay on their index cancer treatment, their quality of life, and the impact on the dog owner?”, 16 indicated that they rate CID as having a moderate to large negative impact on a dog’s ability to stay on their index cancer treatment, on a dog’s quality of life, and on the dog’s owner.